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Abstract
Objective—Identification of a particular cause of meningoencephalitis can be challenging due to 
the myriad bacteria, viruses, fungi, and parasites that can produce overlapping clinical phenotypes, 
frequently delaying diagnosis and therapy. Metagenomic deep sequencing (MDS) approaches to 
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infectious disease diagnostics are known for their ability to identify unusual or novel viruses and 
thus are well suited for investigating possible etiologies of meningoencephalitis.
Methods—We present the case of a 74 year-old woman with endophthalmitis followed by 
meningoencephalitis. MDS of her cerebrospinal fluid (CSF) was performed to identify an 
infectious agent.
Results—Sequences aligning to Balamuthia mandrillaris ribosomal RNA genes were identified 
in the CSF via MDS. Polymerase chain reaction (PCR) subsequently confirmed the presence of B. 
mandrillaris in CSF, brain tissue, and vitreous fluid from the patient’s infected eye. B. 
mandrillaris serology and immunohistochemistry for free-living amoebas on the brain biopsy 
tissue were positive.
Interpretation—The diagnosis was made using MDS after the patient had been hospitalized for 
several weeks and subjected to costly and invasive testing. MDS a powerful diagnostic tool with 
the potential for rapid and unbiased pathogen identification leading to early therapeutic targeting.
Keywords
Metagenomics; next-generation sequencing; primary amoebic meningoencephalitis; Balamuthia 
mandrillaris; encephalitis
Introduction
Meningoencephalitis presents significant diagnostic challenges due in part to the large 
number of possible underlying causes. These include infectious, inflammatory, 
paraneoplastic, and toxic-metabolic etiologies, many of which can present with similar 
clinical phenotypes. Furthermore, confirming an infectious etiology can be challenging, as 
many pathogen-specific serologic and polymerase chain reaction (PCR) assays are 
expensive, time-consuming and have poor operating characteristics. Culture-based 
approaches, though they can often detect multiple species, are also limited, as many 
infectious agents require special culture conditions and prolonged incubation times. 
Standard culture protocols are also not commercially available for many organisms.
Metagenomics is the study of genetic material recovered from an environmental sample, 
including bodily fluids and tissues. Rapid advances in sequencing technology and 
bioinformatics have made an unbiased deep sequencing approach to metagenomics an 
increasingly feasible method for rapidly interrogating all the genetic material contained in a 
sample. We previously reported on the ability of metagenomic deep sequencing (MDS) of 
cerebrospinal fluid (CSF) to identify the cause of infectious meningoencephalitis in real 
time, leading to a dramatic improvement in a patient’s medical condition.1 Here, we 
describe a case of meningoencephalitis in a 74-year-old woman that illustrates the ability of 
an MDS-based approach to identify an amoebic cause of meningoencephalitis. Our patient 
had had an extensive diagnostic workup including two brain biopsies, but a final diagnosis 
was not reached before she died. Shortly before her death, a sample of CSF was submitted 
for MDS, which led to the identification of Balamuthia mandrillaris, a rare and almost 
uniformly fatal cause of meningoencephalitis. This diagnosis was later confirmed by the 
Centers for Disease Control and Prevention (CDC), the California Department of Public 
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Health (CA DPH), and analysis of additional immunohistochemical stains and additional 
sections of brain biopsy tissue. MDS provides an efficient and unbiased diagnostic approach 
to identify culprit central nervous system (CNS) infections and may generate large cost-
savings when used to improve diagnosis rates in patients with costly conditions like 
meningoencephalitis.2 Early treatment guided by rapid and accurate diagnosis may also 
improve outcomes in cases such as these in which delayed diagnosis has likely contributed 
to historically poor outcomes.
Case Report
A 74-year old Chinese woman with a history of rheumatoid arthritis treated with 
hydroxychloroquine sulfate presented to our hospital with altered mental status. She had 
immigrated to the United States from China approximately eight years prior and had been 
independent in all her activities. She did not use tobacco, alcohol, or illicit drugs.
In the four weeks preceding hospitalization at our institution, she was admitted three times 
to two other facilities. On each occasion she was evaluated for intermittent fevers and mildly 
altered mental status. On the second admission she was diagnosed with endophthalmitis and 
treated empirically with intravitreal vancomycin, ceftazidime and voriconazole, though 
vitreal and blood cultures eventually showed no growth, and PCRs on the vitreous fluid for 
herpes simplex virus, cytomegalovirus and toxoplasmosis ultimately proved negative. In 
addition, she was started on therapy for Toxoplasma gondii in the setting of a positive serum 
IgM titer (see Table 1). Although her vision did not improve, she was briefly discharged but 
then brought back to the hospital for a third admission when a cervical spine MRI performed 
to evaluate spinal tenderness was incidentally noted to show a T2 hyperintensity in the pons. 
A subsequent brain MRI showed small areas of restricted diffusion in multiple vascular 
territories consistent with infarcts (see Figure 1A). A stroke work-up including a trans-
esophageal echocardiogram was unrevealing except for paroxysmal atrial fibrillation. The 
patient was discharged a third time, now on warfarin for presumed cardioembolic strokes.
Although she had been ruled out for acid-fast bacilli during her second hospitalization, the 
patient presented to our institution two days later for an evaluation at the city’s tuberculosis 
(TB) clinic given her recent history of pneumonia and demographic risk factors. At the TB 
clinic, it was found that her neurologic status had significantly deteriorated since her 
discharge two days prior. She was transferred directly to the Emergency Department where 
her vital signs were: temperature 103°F; heart rate 111 beats per minute; blood pressure 
123/81 mm Hg; oxygen saturation 93% on room air. She moved all four extremities 
spontaneously but was unable to follow commands or verbalize, resulting in a Glasgow 
Coma Scale score of 6. At this point she was intubated for airway protection and admitted to 
the intensive care unit (ICU).
Initial laboratory evaluation revealed a white blood cell count of 12.6 × 103 cells/µL, 
hemoglobin of 13.7 g/dL, serum sodium of 129 mEq/L, and serum glucose of 135 mg/dL. 
CSF analysis demonstrated 13 red blood cells/mm3, 347 white blood cells/mm3 (57% 
neutrophils, 11% monocytes, 31% lymphocytes, 1% eosinophils), glucose 30 mg/dL, and 
protein 71 mg/dL. Brain MRI demonstrated innumerable ring enhancing and diffusion-
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restricted supra- and infratentorial lesions that were felt to be most consistent with abscesses 
as well as severe obstructive hydrocephalus.
On the first day of her hospitalization she was initiated on empiric treatment for bacterial 
brain abscesses with vancomycin, cefepime, and metronidazole. Blood, urine, and CSF 
bacterial and fungal cultures were eventually negative, as were CSF tests for neurosyphilis, 
TB, and Cryptococcus (see Table 1). Both CSF and serologic tests for toxoplasmosis were 
negative. Despite broad antibiotic coverage, she continued to deteriorate with progressive 
loss of motor activity and subsequently brainstem reflexes over the following 16 days. On 
hospital day 10, a repeat lumbar puncture showed worsening pleocytosis with a more 
prominent eosinophilia (see Table 1). Given these findings, broad-spectrum antibiotics were 
stopped on day 10, and she was initiated on anti-TB and anti-fungal therapy. A brain biopsy 
performed on day four was non-diagnostic, revealing only mild gliosis and no inflammatory 
infiltrate or microorganisms. A repeat biopsy one week later (day 11) demonstrated a severe 
necrotizing vasculitis of unclear etiology, with a prominent component of eosinophils, 
chronic inflammatory cells, and neutrophils but without a significant granulomatous 
component. Repeat brain MRI on hospital day 14 demonstrated an increase in the number 
and size of her brain lesions as well as interval development of basilar meningitis (see 
Figure 1B and 1C). Her worsening cerebral edema was refractory to management with 
hyperosmolar therapy, as well as to the extraventricular drain that was placed during her 
second brain biopsy. The patient ultimately became hemodynamically unstable, likely due to 
elevated intracranial pressure, and required multiple vasopressors. Her family opted for 
comfort care measures to be instituted, and the patient was extubated and expired on day 17 
of her hospitalization.
Methods
On day nine of the patient’s hospitalization, a sample of CSF was submitted for unbiased 
MDS under a research protocol for the identification of potential pathogens approved by the 
institutional review boards of San Francisco General Hospital (SFGH) and the University of 
California, San Francisco (UCSF). Samples were processed for MDS analysis as previously 
described.1 Briefly, total ribonucleic acid (RNA) was extracted from CSF. Samples were 
randomly amplified to double stranded cDNA using the NuGEN Ovation v.2 kit (NuGEN, 
San Carlos, CA) for low nucleic acid content samples, and MDS libraries were constructed 
using the Nextera protocol (Illumina, San Diego, CA) as previously described.1 Library size 
and concentration were determined using the Blue Pippin (Sage Science, Beverly, MA) and 
Kapa Universal qPCR kit (Kapa Biosystems, Woburn, MA), respectively. Samples were 
sequenced on an Illumina HiSeq 2500 instrument using 135/135 base pair (bp) paired-end 
sequencing. The paired-end sequences were analyzed for pathogens using a rapid 
computational pipeline for pathogen detection as described below.
RESULTS
Identification of Balamuthia sequences in CSF
The MDS of total RNA from the patient sample yielded 19,642,962 paired-end reads 
representing 5.2 gigabases total. The data were analyzed using a rapid computational 
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pipeline developed at our institution to classify MDS reads and identify potential pathogens 
by comparison to the entire National Center for Biotechnology Information (NCBI) 
nucleotide (nt) reference database. Briefly, paired-end reads were quality filtered using 
PriceSeqFilter, a component of the PRICE assembler, followed by alignment to the human 
reference genome (hg19) using bowtie2 v2.2.4.3, 4 Unaligned reads that were at least 95% 
identical were compressed by cd-hit (v4.6.1), resulting in a total of 33,093 remaining reads, 
representing approximately 0.1% of the original data.5, 6 These reads were then used as 
queries to search the NCBI nt database using gsnapl (v2014-10-16).7 Over 97% of these 
reads yielded gsnapl alignments to vertebrate sequences (human reads not filtered by 
bowtie), and known contaminants found in laboratory reagents.
After filtering, our analysis identified B. mandrillaris as the most highly represented 
organism with 81 reads mapping to the three published B. mandrillaris genes in the NCBI 
repository. Twenty-nine other individually barcoded patient CSF samples (including a water 
control) were included in the same sequencing run, and none contained reads that aligned to 
Balamuthia, nor had Balamuthia reads ever been detected in this laboratory previously. The 
complete pipeline run time for this analysis was 1hr 5min.
These results informed a retrospective bioinformatic analysis of the original dataset wherein 
the raw MDS reads were directly aligned to the three available B. mandrillaris gene 
sequences. The alignment yielded ~3500 read pairs mapping concordantly to the B. 
mandrillaris genes, representing only 0.018% of the original dataset. A random sample (30 
reads) of the aligned sequences was used to seed an assembly using the targeted assembler 
PRICE (v1.2), ultimately generating an 806 nt contig corresponding to the B. mandrillaris 
16S ribosomal RNA (rRNA) gene (GenBank accession number KP990616).3
Confirmatory testing for B. mandrillaris
The presence of B. mandrillaris was confirmed via multiple methods. Using a published 
Centers for Disease Control and Prevention (CDC) polymerase chain reaction (PCR) 
protocol, the 18s rRNA gene from B. mandrillaris was detected in the patient’s formalin 
fixed brain biopsy tissue from the second brain biopsy, CSF, and vitreous fluid.8 The PCR 
products were Sanger sequenced (Quintara Biosciences, Albany, CA) and confirmed to be 
sequences from the Balamuthia 18s rRNA gene. Based on the findings of the CSF MDS 
study, material from the patient’s second brain biopsy was re-evaluated with additional level 
sections, which revealed organisms consistent with amoeba within vessels and extending 
into the neural parenchyma (see Figure 1D). The Infectious Diseases Pathology Branch at 
the CDC performed confirmatory immunohistochemistry for free-living amoeba on the brain 
biopsy tissue (see Figure 1E), and the CA DPH determined that the patient had a borderline 
positive serology for B. mandrillaris (see Table 1).9
Discussion
We present the case of a woman with several weeks of progressive meningoencephalitis that 
eventually proved fatal despite a three week ICU stay, various antimicrobial regimens, 
multiple serological and CSF studies and two brain biopsies. This extensive testing did not 
reveal the cause of her syndrome; however, MDS of her CSF demonstrated the etiologic 
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agent, B. mandrillaris. This finding was subsequently confirmed by PCR and by 
immunohistochemistry of the brain biopsy tissue. To our knowledge, this is the first case in 
which unbiased MDS has proven useful for identifying an amoebic infection in the context 
of a critical illness. The identification of B. mandrillaris was particularly notable given that 
sequences for only three of the likely ~15,000 B. mandrillaris genes are publicly available in 
the NCBI database utilized by our bioinformatics pipeline for pathogen identification. 
Clearly, additional genomic information for this enigmatic pathogen would be useful in the 
context of future sequence-based diagnostic assays, and for the purpose of identifying new 
therapeutic targets.
Since it was first isolated in 1986, B. mandrillaris has been recognized as a rare cause of 
amoebic encephalitis in humans, with approximately 200 cases reported worldwide.10, 11 
The amoeba is distributed worldwide in soil, fresh, and saltwater sources, and causes disease 
in both immunocompetent and immunocompromised hosts.10 In fact, heavy soil exposure 
has been cited as a possible risk factor for developing a B. mandrillaris infection.12 
Although our patient had a small garden behind her house, she was not known to be an avid 
gardener. She was also not heavily immunosuppressed for her rheumatoid arthritis.
The infection commonly manifests with nonspecific symptoms, including fever, headache, 
nausea, vomiting, seizures, and focal neurologic signs.13–16 As in the case presented here, 
imaging may reveal the presence of nodular lesions involving gray and white matter, with or 
without ring-enhancement; disease progression commonly leads to vasogenic edema and 
mass effect.10
The period of incubation at the site of primary infection is variable, as it may precede by 
months the development of encephalitis. From the initial site, the organisms migrate to the 
CNS via the blood stream, where they proliferate, inducing a granulomatous inflammation 
that progresses for a period of weeks. Amoebic encephalitis can show various histologic 
patterns, and in this case no granulomatous component was seen in the brain biopsy 
specimen; Balamuthia in particular is known to present with a range of inflammatory 
patterns.17, 18 To our knowledge, this is the first time that an ocular infection with B. 
mandrillaris has been described. An unsuccessful attempt was made to culture B. 
mandrillaris from the CSF, but no attempt at amoebic culture was made from the remaining 
vitreous fluid given its small volume (i.e., 30 uL) and because it had been frozen for an 
extended period of time in a −70°C freezer. The vitreous fluid was collected in the hospital 
under sterile conditions when the patient first presented with endophthalmitis. All standard 
precautions were taken in the laboratory to prevent cross contamination. A negative PCR 
water control conducted simultaneously was negative for B. mandrillaris. The positive 
vitreous fluid PCR result was repeated in triplicate and confirmed by Sanger sequencing.
There are only ten reported cases of patients surviving B. mandrillaris mengioencephalitis, 
in part because of extensive disease at the time of diagnosis and a lack of well-developed 
treatment protocols. Pentamidine, clarithromycin, fluconazole, and sulfadiazine have been 
used in patients who have survived the infection.19, 20 Recently, miltefosine, in combination 
with some of these other agents, has shown some promise and is approved by the Food and 
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Drug Administration as an investigational treatment of granulomatous encephalitis caused 
by B. mandrillaris.21
Diagnosis of B. mandrillaris has traditionally relied on its identification in tissue samples. 
CSF analysis usually reveals a mononuclear pleocytosis, high protein levels and normal to 
low glucose concentrations.22, 23 Culturing Balamuthia amoebae is very challenging, 
requiring a feeder tissue monolayer such as monkey kidney cells. Growth typically takes 
several weeks before the amoebae start to proliferate.24 PCR and antibody detection assays 
have been developed as well; however, the diagnosis is not frequently entertained and extant 
assays are not widely available.8, 9
As an alternative to conventional assays, MDS represents an unbiased and rapid diagnostic 
tool, especially for vexing cases, such as the one presented here. One criticism of an MDS-
based approach is the perceived high-cost of the assay. However, we believe this technique 
represents a significant cost-savings compared to the lengthy hospitalizations, diagnostic 
tests, and empiric therapies frequently associated with cases of idiopathic encephalitis.2 For 
example, during our patient’s final hospitalization, we estimate the reimbursement from 
insurance, which, after adjustments, was only 18% of charges billed, to be over $140,000. 
We calculated reimbursement for her antimicrobials alone to total $8,000, the ICU stay over 
$50,000, her laboratory testing over $14,000, and brain biopsies $30,000. Meanwhile, we 
estimate the cost of MDS for a single sample to total approximately $2,000 for materials and 
labor. Given current trends in genomic technology development, this cost will likely 
continue to drop significantly. Furthermore, though turnaround time for MDS in this case 
was six days, this was largely due to staffing for this experimental protocol. We have 
already shown that with adequate staffing, this protocol can be completed in under 48 
hours.1 This represents a significant advantage compared to many of the culture-dependent 
assays mentioned above. With continued decreases in cost and time, and corresponding 
increases in sequencing depth and advances in sequencing library preparation techniques, it 
is foreseeable that MDS could be deployed as a frontline diagnostic tool for patients with 
difficult-to-diagnose infectious syndromes like encephalitis. Early diagnosis through MDS 
may eventually supplement or replace the numerous and costly diagnostic assays and 
procedures currently employed and, more importantly, potentially improve patient 
outcomes. Given that our patient’s eye infection preceded her meningoencephalitis, it is 
tantalizing to envision how early detection of B. mandrillaris in the vitreous fluid via MDS 
may have created a treatment window that could have headed off the devastating and lethal 
CNS manifestations of her infection.
Acknowledgements
This work was supported by the American Brain Foundation Clinical Research Training Fellowship (to MRW); 
Howard Hughes Medical Institute (to JLD); National Center for Advancing Translational Sciences of the NIH 
[KL2TR000143] (to MRW and JMG). The latter’s contents are solely the responsibility of the authors and do not 
necessarily represent the official views of the NIH. The findings and conclusions are those of the authors and do not 
necessarily represent the official position of the US Department of Health and Human Services. We would like to 
thank Jessica Lund and Eric Chow at the UCSF Center for Advanced Technology for their expertise and assistance 
operating the Illumina sequencer.
Wilson et al. Page 7














1. Wilson MR, Naccache SN, Samayoa E, et al. Actionable diagnosis of neuroleptospirosis by next-
generation sequencing. The New England journal of medicine. 2014 Jun 19; 370(25):2408–2417. 
[PubMed: 24896819] 
2. Vora NM, Holman RC, Mehal JM, Steiner CA, Blanton J, Sejvar J. Burden of encephalitis-
associated hospitalizations in the United States: 1998–2010. Neurology. 2014 Feb 4; 82(5):443–
451. [PubMed: 24384647] 
3. Ruby JG, Bellare P, Derisi JL. PRICE: software for the targeted assembly of components of (Meta) 
genomic sequence data. G3. 2013 May; 3(5):865–880. [PubMed: 23550143] 
4. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 2012 Apr; 
9(4):357–359. [PubMed: 22388286] 
5. Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation 
sequencing data. Bioinformatics. 2012 Dec 1; 28(23):3150–3152. [PubMed: 23060610] 
6. Li W, Godzik A. Cd-hit: a fast program for clustering and comparing large sets of protein or 
nucleotide sequences. Bioinformatics. 2006 Jul 1; 22(13):1658–1659. [PubMed: 16731699] 
7. Wu TD, Nacu S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. 
Bioinformatics. 2010 Apr 1; 26(7):873–881. [PubMed: 20147302] 
8. Qvarnstrom Y, Visvesvara GS, Sriram R, da Silva AJ. Multiplex real-time PCR assay for 
simultaneous detection of Acanthamoeba spp. Balamuthia mandrillaris, and Naegleria fowleri. 
Journal of clinical microbiology. 2006 Oct; 44(10):3589–3595. [PubMed: 17021087] 
9. Schuster FL, Yagi S, Wilkins PP, Gavali S, Visvesvara GS, Glaser CA. Balamuthia mandrillaris, 
agent of amebic encephalitis: detection of serum antibodies and antigenic similarity of isolates by 
enzyme immunoassay. The Journal of eukaryotic microbiology. 2008 Jul-Aug;55(4):313–320. 
[PubMed: 18681845] 
10. Lorenzo-Morales J, Cabello-Vilchez AM, Martin-Navarro CM, Martinez-Carretero E, Pinero JE, 
Valladares B. Is Balamuthia mandrillaris a public health concern worldwide? Trends in 
parasitology. 2013 Oct; 29(10):483–488. [PubMed: 23988231] 
11. Visvesvara GS, Martinez AJ, Schuster FL, et al. Leptomyxid ameba, a new agent of amebic 
meningoencephalitis in humans and animals. Journal of clinical microbiology. 1990 Dec; 28(12):
2750–2756. [PubMed: 2280005] 
12. Schuster FL, Glaser C, Honarmand S, Maguire JH, Visvesvara GS. Balamuthia amebic 
encephalitis risk, Hispanic Americans. Emerging infectious diseases. 2004 Aug; 10(8):1510–1512. 
[PubMed: 15503402] 
13. Griesemer DA, Barton LL, Reese CM, et al. Amebic meningoencephalitis caused by Balamuthia 
mandrillaris. Pediatric neurology. 1994 May; 10(3):249–254. [PubMed: 8060431] 
14. Rowen JL, Doerr CA, Vogel H, Baker CJ. Balamuthia mandrillaris: a newly recognized agent for 
amebic meningoencephalitis. The Pediatric infectious disease journal. 1995 Aug; 14(8):705–710. 
[PubMed: 8532431] 
15. Denney CF, Iragui VJ, Uber-Zak LD, et al. Amebic meningoencephalitis caused by Balamuthia 
mandrillaris: case report and review. Clin Infect Dis. 1997 Dec; 25(6):1354–1358. [PubMed: 
9431377] 
16. Reed RP, Cooke-Yarborough CM, Jaquiery AL, et al. Fatal granulomatous amoebic encephalitis 
caused by Balamuthia mandrillaris. The Medical journal of Australia. 1997 Jul 21; 167(2):82–84. 
[PubMed: 9251693] 
17. Schuster FL, Yagi S, Gavali S, et al. Under the radar: balamuthia amebic encephalitis. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 
Apr 1; 48(7):879–887. [PubMed: 19236272] 
18. Guarner J, Bartlett J, Shieh WJ, Paddock CD, Visvesvara GS, Zaki SR. Histopathologic spectrum 
and immunohistochemical diagnosis of amebic meningoencephalitis. Modern pathology : an 
official journal of the United States and Canadian Academy of Pathology, Inc. 2007 Dec; 20(12):
1230–1237.
Wilson et al. Page 8













19. Schuster FL, Visvesvara GS. Axenic growth and drug sensitivity studies of Balamuthia 
mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. Journal of 
clinical microbiology. 1996 Feb; 34(2):385–388. [PubMed: 8789020] 
20. Deetz TR, Sawyer MH, Billman G, Schuster FL, Visvesvara GS. Successful treatment of 
Balamuthia amoebic encephalitis: presentation of 2 cases. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America. 2003 Nov 15; 37(10):1304–1312. 
[PubMed: 14583863] 
21. Martinez DY, Seas C, Bravo F, et al. Successful treatment of Balamuthia mandrillaris amoebic 
infection with extensive neurological and cutaneous involvement. Clin Infect Dis. 2010 Jul 15; 
51(2):e7–e11. [PubMed: 20550438] 
22. Jung S, Schelper RL, Visvesvara GS, Chang HT. Balamuthia mandrillaris meningoencephalitis in 
an immunocompetent patient: an unusual clinical course and a favorable outcome. Archives of 
pathology & laboratory medicine. 2004 Apr; 128(4):466–468. [PubMed: 15043486] 
23. Kodet R, Nohynkova E, Tichy M, Soukup J, Visvesvara GS. Amebic encephalitis caused by 
Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathology, 
research and practice. 1998; 194(6):423–429.
24. Schuster FL. Cultivation of pathogenic and opportunistic free-living amebas. Clinical microbiology 
reviews. 2002 Jul; 15(3):342–354. [PubMed: 12097243] 
Wilson et al. Page 9













Figure 1. Neuroimaging and Neuropathology
A, Axial T2-weighted / fluid attenuated inversion recovery (FLAIR) brain magnetic 
resonance imaging (MRI) demonstrating multiple hyperintensities (arrows) which 
correspond to areas of restricted diffusion on diffusion weighted imaging (not shown). B, 
Axial T2-weighted / FLAIR brain MRI demonstrating progression in the size and number of 
hyperintensities (arrows) visualized in the MRI in panel A. C, Post-contrast axial T1-
weighted brain MRI demonstrating multiple ring enhancing lesions (white arrow) and 
basilar meningitis (yellow arrow) as well as severe hydrocephalus. D, Periodic acid-Schiff 
stained section of brain parenchyma shows necrotizing vasculitis, chronic inflammatory 
cells, and a population of amoebic trophozoites that closely resemble macrophages (arrows), 
400×. The majority of the tissue showed a robust necrotizing vasculitis with mixed 
inflammation including macrophages and numerous eosinophils. E, Immunohistochemistry 
for free-living amoebas highlights numerous B. mandrillaris trophozoites, 400× (courtesy of 
M.K.K., CDC).
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